Pipeline
Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria. Extensive Phase I data have demonstrated that BC-3781 can achieve therapeutically relevant blood and tissue levels in man with excellent tolerability when administered by either oral or intravenous routes. The company also has a Phase I topical pleuromutilin product candidate, BC-7013.